Rosalind Advisors, Inc.

TORONTO, null · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$309.3M2026 Q3+ $2.6M options (notional, not included)
Positions46
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.71.6%

Rosalind Advisors, Inc. reported 46 positions worth $309.3M as of September 30, 2026 (13F filed November 16, 2026). Largest holding: DCTH (16.9%). Biggest move: new buy REPL ($13.2M).

10 / 46 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 DCTHDelcath Systems$52.7M16.90%3,300,389——+24.4%
▸ 2 VSTMVerastem$34.1M10.94%4,236,509——-4.3%
▸ 3 FENCFennec Pharmaceuticals$34.0M10.89%3,188,001——+9.1%
▸ 4 XERSXeris Biopharma$24.7M7.92%2,582,647——+74.7%
▸ 5 HELPHelus Pharma$17.1M5.47%1,387,969——-27.8%
▸ 6 SVRASavara$16.4M5.26%3,178,121——-10.1%
▸ 7 REPLReplimune$13.2M4.25%1,000,000——+61.7%
▸ 8 VORVor Biopharma$11.6M3.73%609,199——-0.6%
▸ 9 MDWDMediWound$10.3M3.31%749,054——-1.6%
▸ 10 XFORX4 Pharmaceuticals$9.3M2.99%3,214,766——+7.6%

Pro Feature

The remaining 36 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Rosalind Advisors, Inc. hold as of Q3 2026?

Rosalind Advisors, Inc. reported 46 positions worth $309.3M in its Q3 2026 13F filing. Largest positions: DCTH (16.9%), VSTM (10.9%), FENC (10.9%), XERS (7.9%) and HELP (5.5%).

What did Rosalind Advisors, Inc. buy in Q3 2026?

New positions: REPL, TARA, RCKT, ABOS and FEMASYS INC (15 in all). Added to: AQST, PEPG, VSTM, BIOFRONTERA INC and MYOMO INC (10 in all).

What did Rosalind Advisors, Inc. sell in Q3 2026?

Reduced: HELP, AVIR, XERS, PCVX and TALPHERA INC (9 in all). Sold out entirely: CLDX, CG ONCOLOGY INC, ISHARES TR and TENAX THERAPEUTICS INC.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.